• Luciana Ricca Gonçalves and Robalo NunesAntónioAServiço de Imuno-hemoterapia. Hospital das Forças Armadas. Lisboa. Portugal..
• Serviço de Imuno-hemoterapia. Centro Hospitalar Universitário de São João. Porto. Portugal.
• Acta Medica Port. 2022 May 2; 35 (5): 394-398.

AbstractDabigatran is a direct oral anticoagulant used to prevent stroke and systemic embolism in patients with atrial fibrillation. In situations that require the urgent reversal of its anticoagulant activity, such as in the case of severe bleeding that is life-threatening; urgent/ emergent surgery or invasive procedures with significant bleeding risk; and the need for thrombolysis in a patient with ischemic stroke, several measures can be taken, including the use of its specific reversal agent, idarucizumab. Based on the guidelines for the use of reversal agents for oral anticoagulants, and on the clinical experience of reversal of dabigatran, a practical guide is presented for use in clinical situations where reversal of dabigatran anticoagulation is required, including the use of idarucizumab. The adoption of this type of guideline contributes to therapeutic optimization and, consequently, greater reversal efficiency and a better resource management.

13 keywords...

hide…